On January 15, 2009, Degnan, Andrew P.; Tora, George O.; Denhart, Derek J.; Vrudhula, Vivekananda M.; Macor, John E.; Bronson, Joanne J. published a patent.Formula: C12H14F3NO2 The title of the patent was Preparation of substituted heterocyclic ethers as inhibitors of NK-1 and SERT and their use in treating CNS disorders. And the patent contained the following:
The invention encompasses compounds of Formula I (wherein R1 is H or alkyl; R2 is H, alkyl, cyanoalkyl, haloalkyl, etc.; R3 is H or alkyl; Ar1 is substituted Ph or pyridinyl; Ar2 is substituted indolyl, indazolyl, benzimidazolyl, or benzotriazolyl), including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. The compounds of Formula I demonstrate inhibition of neurokinin-1 or serotonin reuptake or both and can be used therefore to treat conditions associated with aberrant levels of tachykinins or serotonin or both. Such conditions are anxiety, depression, obsessive compulsive disorder, bulimia, panic disorder, posttraumatic stress disorder, alc. dependence, or urinary incontinence. Synthetic procedures for preparing I are exemplified. Example compound II, prepared by removing the protecting groups from the corresponding intermediate, had an NK-1 and SERT IC50 values of 0.01-100 nM in binding assays. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Formula: C12H14F3NO2
The Article related to preparation heterocyclic ether nk1 sert inhibitor cns disorder treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C12H14F3NO2
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics